1. Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer 
David M. Guttmann, MD, MTR, Nandita Mitra, PhD, Justin Bekelman, MD, James M. Metz, MD, John Plastaras, MD, PhD, Weiwei Feng, MS, Samuel Swisher-McClure, MD, MSHP 
Journal of Thoracic Oncology 
Volume 12, Issue 7, Pages (July 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Temporal trends in use of chemotherapy alone and chemotherapy with low- or high-dose radiotherapy in metastatic esophageal cancer. The Spearman test for trend was significant for the trend of increasing utilization of chemotherapy alone over time (p trend < 0.001).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Inverse probability of treatment weighting adjusted overall survival in patients with metastatic esophageal cancer treated with chemotherapy alone (no radiotherapy [RT]), radiation doses less than 5040 cGy, or radiation doses of 5040 cGy or higher. The shaded region surrounding each line represents the upper and lower bounds of the 95% confidence interval. For the comparison, the hazard ratio is 0.72 (95% confidence interval: 0.70–0.74, p ≤ 0.001).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions